Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...
Understand the regulatory and policy considerations for running clinical trial recruitment campaigns on nontraditional or ...
As clinical research evolves, integrated technologies are reshaping patient and site experiences through AI, remote monitoring, and next-generation telehealth. Join IQVIA experts Chris Driver and Dan ...
In today’s ACT Brief, we look at how Trialbee evaluates nontraditional digital platforms for patient recruitment, review new ...
Learn how demographic and behavioral insights inform platform-specific messaging, creative formats, and call-to-action ...
Tremfya demonstrated sustained reduction in PsA symptoms and inhibited structural damage progression at 48 weeks in the APEX trial. Patients switching from placebo to Tremfya experienced a 57% ...
Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok ...
In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s ...
FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...
Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...
In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...
The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback